BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Arcus Medical Receives Reimbursement Approval from the Prescription Pricing Authority in the United Kingdom


4/15/2009 12:16:40 PM

Charlotte, North Carolina, April 15, 2009 – Arcus Medical, LLC (Arcus), a leading innovator and manufacturer of patented medical devices, announced today that its afex® brand of products for management of male incontinence has been approved for reimbursement by the Prescription Pricing Authority (PPA) in the United Kingdom.

Sales and distribution of afex® products will be led by Mr. Darren Breen of iMEDicare, Ltd. in the UK. Since receiving CE Certification for afex® in 2008, the UK market was selected as the strategic center for developing scalable sales and distribution channels to additional EU countries.

“We estimate that there are approximately 3 million men in the UK managing urinary incontinence. The market potential for afex® in the UK is very compelling and we look forward to developing the UK market with iMEDicare,” said Michael LaCount, President and CEO of Arcus Medical. “Since afex® has been approved for reimbursement by the PPA, afex® can compete with incumbent products primarily on the basis of innovation. We are confident that incontinent men in the UK will react very favorably to afex® and we have every confidence that Mr. Breen can effectively build a robust strategic sales channel for afex® in the UK.”

Mr. Mark Miskie, Arcus founder and its Chief Operating Officer added, “Gaining PPA approval in the UK represents another significant milestone for Arcus Medical as we continue to build our core strategic capabilities and expand our global reach to help both patients and caregivers effectively manage incontinence every day.”

About Arcus Medical

Arcus is dedicated to its mission of improving the quality of life and care for patients and their caregivers around the world. Since its founding in 2004, Arcus has advanced its pipeline of patented and proprietary medical device technologies for management of incontinence to the commercial markets. Arcus markets its innovative products under the afex®, Folex®, and Provent™ brands.

The afex® brand features a patented, non-adhesive receptacle that fits into a comfortable pair of cotton boxer-briefs and couples to a durable, secured collection bag offering an innovative and discreet solution for active, mobility-assisted, or sedentary men with incontinence.

Folex® branded products are specifically designed for extended, unobtrusive comfort and easy connection and release for patients using Foley catheters.

Provent™ branded briefs and pads feature a patented triple layer composite technology which offers superior ability to pull and lock wetness away from the skin while providing breathability for effective wetness protection.

For more information, please visit its website at www.arcusmedical.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES